CenterBook Partners LP Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS)

CenterBook Partners LP raised its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 143.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 208,589 shares of the company's stock after purchasing an additional 122,894 shares during the quarter. CenterBook Partners LP owned 0.23% of NewAmsterdam Pharma worth $5,361,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in NAMS. Legal & General Group Plc grew its holdings in shares of NewAmsterdam Pharma by 24.8% in the 4th quarter. Legal & General Group Plc now owns 22,946 shares of the company's stock valued at $590,000 after acquiring an additional 4,556 shares in the last quarter. Invesco Ltd. bought a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $3,869,000. Ovata Capital Management Ltd bought a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at $3,855,000. Pamalican Asset Management Ltd acquired a new position in NewAmsterdam Pharma during the fourth quarter worth $771,000. Finally, Geode Capital Management LLC lifted its stake in NewAmsterdam Pharma by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 88,544 shares of the company's stock valued at $2,276,000 after acquiring an additional 2,222 shares during the last quarter. Institutional investors own 89.89% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on NAMS shares. HC Wainwright reaffirmed a "buy" rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Needham & Company LLC reiterated a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, April 8th. Royal Bank of Canada restated an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research note on Monday, March 3rd. Finally, Scotiabank upped their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a report on Thursday, February 27th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $43.33.

Remove Ads

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ NAMS traded up $0.77 during trading hours on Monday, hitting $15.89. 353,540 shares of the stock were exchanged, compared to its average volume of 584,352. The company's fifty day simple moving average is $20.26 and its two-hundred day simple moving average is $21.30. The company has a market cap of $1.75 billion, a PE ratio of -6.11 and a beta of -0.01. NewAmsterdam Pharma has a 1-year low of $14.06 and a 1-year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. As a group, sell-side analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now owns 15,000 shares of the company's stock, valued at $305,550. This represents a 90.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director James N. Topper acquired 4,005 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was bought at an average price of $21.02 per share, with a total value of $84,185.10. Following the completion of the acquisition, the director now directly owns 3,012,434 shares of the company's stock, valued at $63,321,362.68. This trade represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 19.50% of the stock is owned by corporate insiders.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.